Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18416938 | 0.79 | SSTR4 (0.40) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL20692404 | 0.78 | HTR2C (0.38) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL30244191 | 0.78 | HTR2C (0.38) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL506105 | 0.78 | RIPK1 (0.40) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL506457 | 0.77 | GRM2 (0.40) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL20692405 | 0.76 | HTR2C (0.39) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL22012402 | 0.76 | HRH3 (0.38) | P2RY1 | |
| SCHEMBL7430459 | 0.75 | RIPK1 (0.59) | HTR2CSLC6A4GRM2RIPK1HTR2A | |
| SCHEMBL506166 | 0.74 | HTR2C (0.36) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL506165 | 0.74 | HTR2C (0.36) | HTR2CSLC6A4GRM2GLSRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |